Viewing details for Yoshihiro Kawaoka

Researcher: Yoshihiro Kawaoka

Areas of Expertise	Influenza virus Molecular mechanism of interspecies transmission of the virus leading to influenza pandemics in humans Molecular pathogenesis of influenza in poultry and mammals Ebola virus Role of viral proteins in pathogenesis and viral replication
Web Site	Yoshihiro Kawaoka's School of Veterinary Medicine Website
Curriculum Vitae (CV)
Issued Patent(s)	9,254,318 - High titer recombinant influenza viruses for vaccines, issued February 2016. 9,222,118 - Screen for inhibitors of filovirus and uses therefor, issued December 2015. 9,157,096 - Reassortant influenza viruses for vaccines, issued October 2015. 9,109,013 - High titer recombinant influenza viruses with enhanced replication in vero cells, issued August 2015. 9,101,653 - Influenza viruses with mutant pb2 gene segment as live attenuated vaccines, issued August 2015.
USPTO Published Applications	20160208223 - High titer recombinant influenza viruses for vaccines, published July 2016. 20160137987 - Recombinant influenza viruses for vaccines and gene therapy, published May 2016. 20160115518 - Screen for inhibitors of filovirus and uses therefor, published April 2016. 20160024479 - High titer recombinant influenza viruses with enhanced replication in vero cells, published January 2016. 20150368621 - Mutations that confer genetic stability to additional genes in influenza viruses, published December 2015.
Recent Publication(s)	Ebola virus stability under hospital and environmental conditions. Westhoff Smith D, Hill-Batorski L, N'jai A, Eisfeld AJ, Neumann G, Halfmann P, Kawaoka Y. J Infect Dis. 2016 Oct 15;214(suppl 3):S142-S144. M2sr, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice. Sarawar S, Hatta Y, Watanabe S, Dias P, Neumann G, Kawaoka Y, Bilsel P. Vaccine. 2016 Sep 30;34(42):5090-8. doi: 10.1016/j.vaccine.2016.08.061. Epub 2016 Sep 3. Complete and incomplete genome packaging of influenza a and b viruses. Nakatsu S, Sagara H, Sakai-Tagawa Y, Sugaya N, Noda T, Kawaoka Y. MBio. 2016 Sep 6;7(5). pii: e01248-16. doi: 10.1128/mBio.01248-16. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T. Antiviral Res. 2016 Aug;132:170-7. doi: 10.1016/j.antiviral.2016.06.007. Epub 2016 Jun 16.
Recent Artistic Works
Collaboration	Shanghai Hile Biopharmaceutical Corp University of Tokyo, International Research Center of Infectious Diseases, Department of Special Pathogens, Microbiology and Immunology, Virology, Institute of Medical Science, Veterinary Microbiology University of Pittsburgh University of Hong Kong, Centre of Influenza Research ERATO Infect Induced Host Responses Project University of Manitoba, National Microbiology Lab, Public Health Agency of Canada, Special Pathogens Program, Medical Microbiology Japan Science and Technology Agency, ERATO, Infectious Induced Host Responses Project Kobe University, International Center of Medical Research and Treatment National Institutes of Health, Laboratory of Virology, Rocky Mountain Veterinary Branch Airlangga University, Veterinary Medicine, Collaborating Research Center
Research Tools
Research Facilities
E-mail Address	[email protected]
Phone Number	608-265-4925
Current University	UW–Madison
Department	Pathobiological Sciences
Title	Professor
Other Appointments
Address Line 1	Room 230
Address Line 2	575 Science Drive
City	Madison
State	WI
Zip Code	53711
Bachelor's Degree	B.S., Hokkaido University, Japan, Veterinary Medicine, 1978
Master's Degree	M.S., Hokkaido University, Japan, 1980
PhD	Ph.D., Hokkaido University, Japan, 1983
Other Degrees	D.V.M., The Ministry of Agriculture and Fishery, Japan, 1978
Technologies Available for Licensing	Plasmids Encoding Avian Influenza Genes Influenza Variant Grows Well in CHO Cells Attenuated Viruses with Mutant Ion Channel Protein Methods for Engineering Influenza Viruses to Carry Defined Mutations Recombinant Influenza Vectors with a Pol II Promoter and Ribozymes for Vaccines and Gene Therapy High Titer Recombinant Influenza Viruses for Vaccines and Gene Therapy Reverse Genetics Approach for Generating Ebola Virus and Other Filoviruses from Cloned DNA Replicating Influenza Mutants with Reduced Sialidase Activity Cell Line for Evaluating Influenza Virus Sensitivity to NA Inhibitors Efficient Generation of Influenza Virus with Adenoviral Vectors Neuraminidase-Deficient Live Influenza Vaccine Recombinant Influenza Viruses for Vaccines and Gene Therapy Safer Ebola Virus and Vaccines Improved Reverse Genetics Method to Produce Influenza Virus Improved Production of Influenza Virus, Including H1N1, for Vaccine Manufacture Attenuated Influenza Viruses for Development of Live Influenza Vaccine High Titer Recombinant Influenza Viruses for Vaccines Inhibitors of Ebola and Other Filoviruses Safer Influenza Vaccine from Replication-Knock Out Virus

Although every effort has been made to provide complete and accurate information, the Wisconsin Alumni Research Foundation (WARF), a private, non-profit, supporting organization to the University of Wisconsin-Madison makes no warranties, express or implied, or representations as to the accuracy of content on this website. WARF assumes no liability or responsibility for any errors or omissions in the information contained in the website or as to the operation of the website.